It's been several months, and a couple of updates have transpired.

The Freedom of Information Act (FOIA) appeals update.
In January 2025, there were 59 appeals ahead, and 6 months later, there are 44 ahead of our appeal. Although the process is slow, we are still in line.

Class Action Lawsuit
On March 27, 2025, a putative class action complaint (the “Securities Complaint”) was filed by alleged stockholder Nihil Kohil against the Company and executives Sandesh Seth, Avinash Desai, Madhuri Vusirikala, and Sergio Giralt (the “Defendants”), styled Kohil v. Actinium Pharmaceuticals, Inc., et al., Case No. 1:25-cv-02553 in the Southern District of New York, wherein, the Securities Complaint alleges that the Defendants made material misrepresentations and omissions concerning the Iomab-B Phase 3 Sierra Trial and the plaintiff asserts claims against all Defendants pursuant to section 10(b) of the Securities Exchange Act (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, as well as additional claims against the individual Defendants pursuant to Section 20(a) of the Exchange Act.  The Complaint purports to assert class action claims on behalf of all persons and entities that purchased or otherwise acquired Actinium securities between October 31, 2022 and August 2, 2024.  Plaintiff seeks unspecified damages.  On May 5, 2025, a derivative shareholder complaint (the “Derivative Complaint”) was filed against the Company and certain of the Company’s directors and officers, alleging derivative liability for the allegations made in the Securities Complaint. 

The filed complaint alleges that defendants made false statements and/or concealed that:
(1) the Company's data from the Phase 3 Sierra
trial was unlikely to satisfy the FDA's guidelines for the acceptance and approval of the Company's targeted radiotherapy, Iomab-B BLA;
(2) the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival that the Company provided to the FDA in an attempt to mitigate the Sierra Trial's poor OS data, were unlikely to satisfy the FDA's guidelines for the acceptance and approval of the Company's Iomab-B BLA;
(3) as a result, the FDA would likely refuse to review the Iomab-B BLA or, if it did consider that BLA, that the application in its current form was unlikely to be approved; and
(4), as a result, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On May 26, 2025, the opportunity to file as lead plaintiff closed.

On June 24, 2025, 
WHEREAS, Kohli and the Handel Family have similarly sized losses of over $600,000 each, and therefore have the “largest financial interest” in the relief sought by the class in the Action (15 U.S.C. §78u-4(a)(3)(B)(iii)(bb));
WHEREAS, Kohli and the Handel Family concluded that jointly prosecuting this Action would be appropriate and assist with the speedy and efficient litigation of the action;

https://app.midpage.ai/document/in-re-actinium-pharmaceuticals-inc-11083366?refG=true